TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07571174: A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Stud

Sponsor: Eli Lilly and Company · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$420,240

Rescue Site Savings

+$280,160

Unlock Full NCT07571174 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07571174 Rescue Dossier →